Metformin hydrochloride: An antihyperglycemic agent

Klepser, Teresa B.; Kelly, Michael

doi:10.1093/ajhp/54.8.893

Cited by 73 publications

(40 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Through a variety of mechanisms, metformin decreases insulin resistance. Initially, the use of metformin in women was for the treatment of anovulation associated with polycystic ovary syndrome (PCOS).…”

Section: Oral Hypoglycemic Medicationsmentioning

confidence: 99%

“…Most maternal adverse events were not significantly different between metformin and insulin treatment groups (Table 2b). 6,25,29 Niromanesh et al reported pregnancy induced hypertension in 5% and 14% as well as cesarean delivery in 43% and 46% of pregnant women with GDM receiving metformin or insulin, respectively. The study by Rowan et al also did not find differences between metformin and insulin treatment groups for pregnancy-induced hypertension (4% vs 6%, respectively) or cesarean delivery (36% vs 38%, respectively).…”

Section: Oral Hypoglycemic Medicationsmentioning

confidence: 99%

See 1 more Smart Citation

Gestational diabetes mellitus management with oral hypoglycemic agents

Ryu

Hays

Hébert

2014

Seminars in Perinatology

View full text Add to dashboard Cite

Oral hypoglycemic agents such as glyburide (second generation sulfonylurea) and metformin (biguanide) are attractive alternatives to insulin due to lower cost, ease of administration, and better patient adherence. The majority of evidence from retrospective and prospective studies suggests comparable efficacy and safety of oral hypoglycemic agents such as glyburide and metformin as compared to insulin when used in the treatment of women with gestational diabetes mellitus (GDM). Glyburide and metformin have altered pharmacokinetics during pregnancy and both agents cross the placenta. In this article, we review the efficacy, safety and dosage of oral hypoglycemic agents for the treatment of gestational diabetes mellitus. Additional research is needed to evaluate optimal dosage for glyburide and metformin during pregnancy. Comparative studies evaluating the effects of glyburide and metformin on long-term maternal and fetal outcomes are also needed.

show abstract

Section: Oral Hypoglycemic Medicationsmentioning

confidence: 99%

Section: Oral Hypoglycemic Medicationsmentioning

confidence: 99%

Gestational diabetes mellitus management with oral hypoglycemic agents

Ryu

Hays

Hébert

2014

Seminars in Perinatology

View full text Add to dashboard Cite

show abstract

“…It exerts an antihyperglycaemic effect by lowering the fasting blood glucose concentrations by approximately 20%, similar to that achieved with a SU. As it promotes modest weight reduction, or at least weight stabilization, it is most often used in obese type 2 diabetics [108]. Administration of insulin and SUs often leads to increased appetite and weight gain [109].…”

Section: Metforminmentioning

confidence: 99%

Diabetes mellitus – an overview

Sonia¹,

Sharma²

2014

Oral Delivery of Insulin

View full text Add to dashboard Cite

“…Sitagliptin phosphate monohydrate (SP) chemically, (3 R )-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3- a ]pyrazin-7(8 H )-yl]-4-(2,4,5-trifluorophenyl)butan-1-one phosphate hydrate [1] is an oral anti-diabetic, which is available in 25 mg, 50 mg and 100 mg tablets for oral administration. SP is used for the improvement of glycemic control in patients with type II diabetes mellitus as monotherapy or combination therapy with metformin or a peroxisome proliferatoractivated receptor gamma (PPAR) agonist (e.g., thiazolidinediones) when the single agent does not provide adequate glycemic control.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination of Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride in Tablets by a Validated UPLC Method

Malleswararao

Suryanarayana²,

Mukkanti³

2012

Sci. Pharm.

View full text Add to dashboard Cite

A novel approach was used to develop and validate a rapid, specific, accurate and precise reverse phase ultra performance liquid chromatographic (UPLC) method for the simultaneous determination of Sitagliptin phosphate monohydrate and Metformin hydrochloride in pharmaceutical dosage forms. The chromatographic separation was achieved on Aquity UPLC BEH C8 100 × 2.1 mm, 1.7 μm, column using a buffer consisting of 10 mM potassium dihydrogen phosphate and 2 mM hexane-1-sulfonic acid sodium salt (pH adjusted to 5.50 with diluted phosphoric acid) and acetonitrile as organic solvent in a gradient program. The flow rate was 0.2 mL min−1 and the detection wavelength was 210 nm. The limit of detection (LOD) for Sitagliptin phosphate monohydrate and Metformin hydrochloride was 0.2 and 0.06 μg mL−1, respectively. The limit of quantification (LOQ) for Sitagliptin phosphate monohydrate and Metformin hydrochloride was 0.7 and 0.2 μg mL−1, respectively. This method was validated with respect to linearity, accuracy, precision, specificity and robustness. The method was also found to be stability-indicating.

show abstract

Metformin hydrochloride: An antihyperglycemic agent

Cited by 73 publications

References 0 publications

Gestational diabetes mellitus management with oral hypoglycemic agents

Gestational diabetes mellitus management with oral hypoglycemic agents

Diabetes mellitus – an overview

Simultaneous Determination of Sitagliptin Phosphate Monohydrate and Metformin Hydrochloride in Tablets by a Validated UPLC Method

Contact Info

Product

Resources

About